SLC5A2 and hydrops fetalis: The EMPEROR-Preserved was a randomized, double-blind, placebo-controlled trial to evaluate the effects of SGLT2 inhibitor, empagliflozin (10 mg once daily), on major HF outcomes in patients with HFpEF.